Skip to main content Back to Top
Advertisement

12/16/2020

Mycophenolate Sodium Delayed-Release Tablets

Products Affected - Description

    • Mycophenolate sodium oral delayed release tablet, Apotex, 180 mg, bottle, 120 count, NDC 60505-2965-07
    • Mycophenolate sodium oral delayed release tablet, Apotex, 360 mg, bottle, 120 count, NDC 60505-2966-07
    • Mycophenolate sodium oral delayed release tablet, Major, 180 mg, bottle, 30 count, NDC 00904-6785-04
    • Mycophenolate sodium oral delayed release tablet, Major, 180 mg, bottle, 120 count, NDC 00904-6785-61
    • Mycophenolate sodium oral delayed release tablet, Major, 360 mg, bottle, 30 count, NDC 00904-6786-04
    • Mycophenolate sodium oral delayed release tablet, Major, 360 mg, bottle, 120 count, NDC 00904-6786-61

Reason for the Shortage

    • Apotex did not provide a reason for the shortage.
    • Major did not provide a reason for the shortage.
    • Mylan has mycophenolate delayed-release tablets available.
    • Novartis has Myfortic delayed-release tablets available.

Available Products

    • Myfortic oral delayed release tablet, Novartis, 180 mg, bottle, 120 count, NDC 00078-0385-66
    • Myfortic oral delayed release tablet, Novartis, 360 mg, bottle, 120 count, NDC 00078-0386-66
    • Mycophenolate sodium oral delayed release tablet, Mylan, 180 mg, bottle, 100 count, NDC 51079-0508-20
    • Mycophenolate sodium oral delayed release tablet, Mylan, 360 mg, bottle, 100 count, NDC 51079-0509-20

Estimated Resupply Dates

    • Apotex has mycophenolate delayed-release tablets on allocation.
    • Major has mycophenolate delayed-release tablets in 100 count bottles on back order and the company estimates release dates in late-January 2021. The 30 count bottles are also on back order and the company estimates release dates in mid-January 2021.

Updated

Created December 16, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.